EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Blocking Th2 Signaling Pathway Alleviates the Clinical Symptoms and Inflammation in Allergic Conjunctivitis

Zhiyan Tao, Wei Liu, Qin Chen, Libo Zhang, Kaiqin She, Guoqing Zhao, Licong Liang, Xuhong Chen, Yiliu Yang, Qin Song, Fang Lu

Investigative Opthalmology & Visual Science · 2023

DOI: 10.1167/iovs.64.10.30 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Investigative Opthalmology & Visual Science, 2023. Verfasst von Zhiyan Tao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. Hauptthemen laut MEDLINE: Conjunctivitis, Allergic. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To explore the role of Th2 signaling pathway in allergic conjunctivitis (AC).

Methods

Serum Th2 cytokines IL-4 or IL-13 of patients with AC were detected using the Meso scale discovery assay to verify the correlation of Th2 immunity and AC pathogenesis. Wistar Han rats were intraperitoneally and subcutaneously injected with ovalbumin (OVA) to establish an experimental AC model and the Th2 signaling pathway was blocked by an investigational neutralizing antibody (CM310). Serum IgE and OVA-specific IgE were detected by ELISA. Conjunctivitis inflammation, infiltration of eosinophils, and mast cell degranulation were detected by histological examination. Immortalized human conjunctival epithelial cells, a conjunctival epithelial cell line, and peripheral blood mononuclear cells of patients with AC were used as the target cells to study the impact of IL-4 or IL-13 on AC progression. Finally, a STAT6 reporter gene system was constructed using immortalized human conjunctival epithelial cells to confirm whether the downstream signaling pathway activated by IL-4 or IL-13.

Results

Serum IL-4 or IL-13 were increased in patients with AC versus healthy individuals. In an OVA-induced rat experimental AC model, blocking the Th2 signaling pathway with CM310, an investigational neutralizing antibody, alleviated the conjunctival symptoms, and decreased serum IgE, suppressed infiltration of eosinophils and mast cell degranulation. Further, an in vitro model showed CM310 suppressed the secretion of inflammatory cytokine from both immune cells and epithelial cells in both patients peripheral blood mononuclear cells and cell line.

Conclusions

Blocking Th2 signaling pathway alleviates the clinical symptoms and inflammation in AC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Conjunctivitis, AllergicHumansRatsAnimalsMiceInterleukin-13Interleukin-4Leukocytes, MononuclearRats, WistarInflammationImmunoglobulin ESignal TransductionCytokinesOvalbuminTh2 CellsMice, Inbred BALB CDisease Models, Animal

Substanzen

Interleukin-13Interleukin-4Immunoglobulin ECytokinesOvalbumin

Autor:innen und Institutionen

  • Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
  • KeyMed Biosciences Inc, Chengdu, Sichuan Province, China.

Zitieren

APA

Tao, Z., Liu, W., Chen, Q., Zhang, L., She, K., Zhao, G., Liang, L., Chen, X., Yang, Y., Song, Q., & Lu, F. (2023). Blocking Th2 Signaling Pathway Alleviates the Clinical Symptoms and Inflammation in Allergic Conjunctivitis. Investigative Opthalmology & Visual Science. https://doi.org/10.1167/iovs.64.10.30

Vancouver

Tao Z, Liu W, Chen Q, Zhang L, She K, Zhao G, et al. Blocking Th2 Signaling Pathway Alleviates the Clinical Symptoms and Inflammation in Allergic Conjunctivitis. Investigative Opthalmology & Visual Science. 2023. doi:10.1167/iovs.64.10.30

BibTeX
@article{Tao2023,
  author = {Tao, Zhiyan and Liu, Wei and Chen, Qin and Zhang, Libo and She, Kaiqin and Zhao, Guoqing and Liang, Licong and Chen, Xuhong and Yang, Yiliu and Song, Qin and Lu, Fang},
  title = {Blocking Th2 Signaling Pathway Alleviates the Clinical Symptoms and Inflammation in Allergic Conjunctivitis},
  journal = {Investigative Opthalmology & Visual Science},
  year = {2023},
  doi = {10.1167/iovs.64.10.30}
}
Kostenlos starten →